ALTHOUGH UNCOMMON, MENINGOCOCCAL DISEASE MOVES FAST AND IS POTENTIALLY FATAL"scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"9

Serogroup B caused almost 1/3 of all US meningococcal cases in patients aged <1 to ≥65 years, from 2005-2014; N=867"scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"15

 

 

ACIP recommendation for MenB vaccination

ACIP recommends that patients 16-23 years of age may be vaccinated against MenB, preferably between ages 16-18."scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"16

  ACIP=Advisory Committee on Immunization Practices.
* Includes serogroup W-135 and serogroups unable to be identified.
 

INDICATION

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals 10 through 25 years of age.

Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.

IMPORTANT SAFETY INFORMATION FOR BEXSERO

  • BEXSERO is contraindicated in cases of hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO
  • Appropriate observation and medical treatment should always be readily available in case of an anaphylactic event following the administration of the vaccine
  • The tip caps of the prefilled syringes contain natural rubber latex, which may cause allergic reactions in latex-sensitive individuals
  • Syncope (fainting) can occur in association with administration of BEXSERO. Ensure procedures are in place to avoid injury from falling associated with syncope
  • The most common solicited adverse reactions observed in clinical trials were pain at the injection site (≥83%), myalgia (≥48%), erythema (≥45%), fatigue (≥35%), headache (≥33%), induration (≥28%), nausea (≥18%), and arthralgia (≥13%)
  • Vaccination with BEXSERO may not provide protection against all meningococcal serogroup B strains
  • Some individuals with altered immunocompetence may have reduced immune responses to BEXSERO
  • Vaccination with BEXSERO may not result in protection in all vaccine recipients

Please see full Prescribing Information for BEXSERO.

References

"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"View all references

All trademarks are the property of their respective owners.

1006228R0 July 2018